Nektar Therapeutics’s filing revealed that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $10403.0 on Feb 19 ’25. In the deal valued at $1.01 per share,10,300 shares were sold. As a result of this transaction, Zalevsky Jonathan now holds 316,604 shares worth roughly $0.26 million.
Then, Wilson Mark Andrew sold 11,040 shares, generating $11,150 in total proceeds. Upon selling the shares at $1.01, the Chief Legal Officer now owns 324,292 shares.
Before that, ROBIN HOWARD W sold 23,774 shares. Nektar Therapeutics shares valued at $24,012 were divested by the President & CEO at a price of $1.01 per share. As a result of the transaction, ROBIN HOWARD W now holds 1,086,901 shares, worth roughly $0.89 million.
B. Riley Securities initiated its Nektar Therapeutics [NKTR] rating to a Buy in a research note published on January 08, 2025; the price target was $4. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Piper Sandler began covering NKTR with “an Overweight” recommendation on November 04, 2024.
Price Performance Review of NKTR
On Monday, Nektar Therapeutics [NASDAQ:NKTR] saw its stock fall -6.61% to $0.82. Over the last five days, the stock has gained 2.26%. Nektar Therapeutics shares have fallen nearly -11.83% since the year began. Nevertheless, the stocks have fallen -9.88% over the past one year. While a 52-week high of $1.93 was reached on 01/07/25, a 52-week low of $0.65 was recorded on 02/12/25. SMA at 50 days reached $0.8898, while 200 days put it at $1.1593.
Levels Of Support And Resistance For NKTR Stock
The 24-hour chart illustrates a support level at 0.7929, which if violated will result in even more drops to 0.7657. On the upside, there is a resistance level at 0.8493. A further resistance level may holdings at 0.8785. The Relative Strength Index (RSI) on the 14-day chart is 46.27, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0099, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.68%. Stochastics %K at 30.62% indicates the stock is a holding.
The most recent change occurred on June 28, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $2 price target.
